Hemogenyx Share News (HEMO)
HEMO Share
HEMO Share
HEMO Share
HEMO Share
HEMO
HEMO Share
HEMO Level 2
HEMO Live
HEMO Broker
HEMO Directors
HEMO Financial
HEMO
HEMO Short
HEMO
Last checked at -
Mon, 26th Apr 2021 09:51
Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Receives convertible loan note conversion notice from Mint Capital Advisors Ltd. Notice is in respect to GBP900,000 worth of notes issued on February 3. Hemogenyx to issue 29.9 million shares at conversion price of GBP0.03015 each.
Current stock price: 2.94 pence, down 16% on Monday
Year-to-date change: down 70%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Hemogenyx Inks USD75,000 Research Deal With Undisclosed Global Firm
Read moreHemogenyx Interim Loss Widens But CDX Antibody Work Progresses
Read more
(Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement with cell therapy outfit Orgenesis to further commercialise its humanised-mouse drug model.
Read more(Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement industry giant Johnson and Johnson to develop a model of systemic lupus erythematosus, the most common form of Lupus.
Read moreLONDON (Alliance News) - Biotechnology company Hemogenyx Pharmaceuticals PLC said on Tuesday it has appointed Marc Feldmann as executive chairman, with effect next will be who
Read more
Last checked at